UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number: 001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On October 14, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated October 14, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | Lakefront Biotherapeutics |
| | | (Registrant) |
| | | |
| | | |
| Date: October 14, 2026 | | /s/ Ying Deng |
| | | Ying Deng |
| | | Authorized Officer |
| | | |
EXHIBIT 99.1
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Previously announced wind-down of the legacy cell therapy activities is substantially complete
Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today
announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology
company developing next-generation armed CAR-T therapies for cancer and formed by experienced executives Paul Stoffels, John Mellors and
Peter Verhaeghe. The preclinical program is based on technology originated from, and research undertaken by AboundBio, which was acquired
by Lakefront NV (previously Galapagos NV) in 2022. The terms of the agreement include an upfront payment of €8 million and the potential
for up to $230 million in milestone payments and a low-single-digit royalty to Lakefront.
The transferred preclinical assets comprise multi-targeting and armed CAR-T constructs designed to improve the potency
and persistence of CAR-Ts and prevent cancer treatment resistance in hematological and solid tumors of high unmet need. Armed Cell Therapeutics
will independently advance these programs.
“I’m pleased we were able to complete this sale of the early-stage cell therapy programs as it provides a
path to continue to advance these assets on behalf of patients. Additionally, it offers Lakefront shareholders the opportunity to benefit
from their potential future progress by the experienced team at Armed Cell Therapeutics,” said Sooin Kwon, Chief Business Officer
of Lakefront. “Lakefront continues to be in an enviable position with a rich legacy of innovation, an exciting newly established
pipeline of T-cell engagers and a strong cash balance.”
Lakefront previously announced its intention to wind down its cell therapy activities following a comprehensive review
of strategic alternatives. This process is substantially complete.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s business development strategy, including the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics
and the expected benefits of such sale; statements regarding Lakefront’s business and financial condition, including Lakefront’s
cash position; statements regarding the wind-down of Lakefront’s cell therapy activities, including regarding the timing and completion
thereof; statements regarding the potential attributes and benefits of the early-stage cell therapy pipeline; statements regarding Armed
Cell Therapeutics’ ability to advance such product candidates into the clinical stage and; statements regarding the opportunity
for Lakefront’s shareholders to benefit from such potential future progress by Armed Cell Therapeutics. Lakefront cautions the reader
that forward-looking statements are based on Lakefront’s management’s current expectations and beliefs and are not guarantees
of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause
actual events, financial condition and liquidity, performance, or achievements, or the industry in which Lakefront operates, to be materially
different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking
statements. In addition, even if Lakefront’s results, performance, financial condition and liquidity, and the development of the
industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments
in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in Lakefront’s filings
and reports with the Securities and Exchange Commission (“SEC”), including in Lakefront’s most recent annual report
on Form 20-F filed with the SEC and Lakefront’s subsequent filings and reports filed with the SEC. Given these risks and uncertainties,
the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of Lakefront’s
operations, financial condition and liquidity, or the industry in which Lakefront operates, are consistent with such forward-looking statements,
they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of
the date of publication of this release. Lakefront expressly disclaims any obligation to update any such forward-looking statements in
this release to reflect any change in Lakefront’s expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
